Methadone Sugar Free Thornton & Ross

Methadone, the active ingredient in Methadone Sugar Free Thornton & Ross, is a synthetic opioid presented as an oral tablet for oral use. It is used to treat opioid dependence and manage chronic pain in adults.

GNH USA supplies Methadone Sugar Free Thornton & Ross as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone is a synthetic opioid used in the management of opioid dependence and chronic pain.

- Opioid dependence: reduces withdrawal symptoms and cravings, supporting maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Opioid detoxification: facilitates supervised withdrawal by stabilising opioid receptors.

Methadone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Constipation - Drowsiness - Sweating - Dry mouth - Headache

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Severe hypotension - Adrenal insufficiency - Seizures - Allergic reactions such as rash or angioedema

When prescribing methadone, several safety considerations should be observed.

- Respiratory disease: assess risk of respiratory depression. - Cardiac monitoring: evaluate QT interval, especially with other QT‑prolonging agents. - Hepatic impairment: adjust dose and monitor liver function. - Dependence risk: avoid abrupt discontinuation to prevent withdrawal. - Pregnancy and lactation: safety unknown, weigh benefits against risks. - Store at ambient temperature: keep in original container, protect from moisture.

Methadone can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, alcohol): risk of profound sedation and respiratory depression. - QT‑prolonging drugs (e.g., quinidine, sotalol): additive cardiac risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase methadone plasma levels. - MAO inhibitors: potential for severe serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other opioids: may enhance opioid effects. - Antidepressants (SSRIs, SNRIs): monitor for serotonin excess. - Antihistamines and anticholinergics: may increase anticholinergic burden.